Propanc Biopharma Provides Shareholder Update

MELBOURNE, Australia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced a shareholder update including recent corporate developments and forecast for 2025/26. As a result of completing a recent initial public offering and up-listing to Nasdaq, the Company is entering a transformational stage as it prepares for the adv ...